文献速递白血病造血干细胞移植与细胞治疗

靶向IDH2R140Q及其他新抗原治疗急性髓系白血病

Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia.
PubMed 文献 · Blood · 2024-01-01

研究探索靶向急性髓系白血病(AML)复发驱动突变产生的新抗原的免疫治疗可行性,聚焦8个基因中14种复发驱动突变,在23名HLA背景各异的个体中检测免疫原性,发现17/23(74%)供者产生反应,以IDH2R140Q最具免疫优势,其特异性T细胞可在体外和体内选择性识别并杀伤表达IDH2R140Q的HLA匹配AML靶细胞。

要点

  • 23名供者中17名(74%)对AML新抗原产生免疫反应。
  • 最具免疫优势的新抗原为IDH2R140Q(17名反应者中11名)、IDH1R132H(7/17)和FLT3D835Y(6/17)。
  • IDH2R140Q特异性T细胞含识别不同HLA等位基因限制性表位的CD4+和CD8+细胞,可选择性杀伤靶细胞。

核心结论

  • 研究结果支持将新抗原特异性T细胞进行临床转化以治疗复发/难治性AML。

研究设计与样本

  • 研究聚焦AML中8个基因的14种复发驱动突变,在23名HLA背景各异的个体中检测其免疫原性。

主要发现

  • 23名供者中17名(74%)产生反应,最具免疫优势的新抗原为IDH2R140Q(17名反应者中11名)、IDH1R132H(17名中7名)和FLT3D835Y(17名中6名)。
  • IDH2R140Q特异性T细胞包含反应性CD4+和CD8+ T细胞,可识别限于不同HLA等位基因的突变特异性表位。
  • 这些neo-T细胞在体外和体内均可选择性识别并杀伤内源性表达IDH2R140Q的HLA匹配AML靶细胞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For patients with high-risk or relapsed/refractory acute myeloid leukemia (AML), allogeneic stem cell transplantation (allo-HSCT) and the graft-versus-leukemia effect mediated by donor T cells, offer the best chance of long-term remission. However, the concurrent transfer of alloreactive T cells can lead to graft-versus-host disease that is associated with transplant-related morbidity and mortality. Furthermore, ∼60% of patients will ultimately relapse after allo-HSCT, thus, underscoring the need for novel therapeutic strategies that are safe and effective. In this study, we explored the feasibility of immunotherapeutically targeting neoantigens, which arise from recurrent nonsynonymous mutations in AML and thus represent attractive targets because they are exclusively present on the tumor. Focusing on 14 recurrent driver mutations across 8 genes found in AML, we investigated their immunogenicity in 23 individuals with diverse HLA profiles. We demonstrate the immunogenicity of AML neoantigens, with 17 of 23 (74%) reactive donors screened mounting a response. The most immunodominant neoantigens were IDH2R140Q (n = 11 of 17 responders), IDH1R132H (n = 7 of 17), and FLT3D835Y (n = 6 of 17). In-depth studies of IDH2R140Q-specific T cells revealed the presence of reactive CD4+ and CD8+ T cells capable of recognizing distinct mutant-specific epitopes restricted to different HLA alleles. These neo-T cells could selectively recognize and kill HLA-matched AML targets endogenously expressing IDH2R140Q both in vitro and in vivo. Overall, our findings support the clinical translation of neoantigen-specific T cells to treat relapsed/refractory AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Leung WK, Torres Chavez AG, French-Kim M, et al. Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. Blood. 2024. PMID: 38241630. doi:10.1182/blood.2023021979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。